← Back to Search

Other

ZN-c3 for Solid Tumors

Phase 1

Recruiting

Research Sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through completion, average of 1 year

Awards & highlights

Study Summary

This trial is testing a new drug, ZN-c3, to see if it is safe and effective when used alone or with other drugs.

Eligible Conditions

Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through completion, average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through completion, average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through completion, average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Dose Escalation

Dose Expansion

Secondary outcome measures

Dose Escalation, Food Effect cohort & Dose Expansion

Dose Escalation, Food Effect cohort and Dose Expansion

Food Effect Cohort

Trial Design

3Treatment groups

Experimental Treatment

Group I: Single Agent Food Effect CohortExperimental Treatment1 Intervention

Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available. This cohort will give subjects the option to continue treatment after PK assessments are completed.

Group II: Single Agent Dose ExpansionExperimental Treatment1 Intervention

Subjects with histologically confirmed recurrent or persistent USC who have had treatment with at least 1 prior platinum-based chemotherapy regimen for management of advanced or metastatic USC and subjects with locally advanced or metastatic malignancy with one or more relevant biomarkers related to DNA damage pathways.

Group III: Single Agent Dose EscalationExperimental Treatment1 Intervention

Subjects with solid tumors with advanced or metastatic disease who are refractory or ineligible to standard therapy(ies) or for whom no standard therapy is available.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncLead Sponsor

7 Previous Clinical Trials

698 Total Patients Enrolled

K-Group BetaLead Sponsor

5 Previous Clinical Trials

582 Total Patients Enrolled

Philippe Pultar, MDStudy DirectorK-Group Beta, a Zentalis Company

2 Previous Clinical Trials

484 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants still able to apply for this research endeavor?

"Clinicaltrials.gov confirms that this ongoing investigation is still seeking participants; the study was first made public on November 1st 2019 and most recently revised on August 12th 2021."

Answered by AI

What is the current rate of enrollment in this study?

"K-Group Beta is the study sponsor, and they are recruiting 110 participants who meet all inclusion criteria between their two sites in Detroit, Michigan (Site 0101) and San Antonio, Texas (Site 0100)."

Answered by AI

Has ZN-c3 been sanctioned by the Federal Drug Administration as a safe and effective therapeutic option?

"Because this is an early-stage trial, ZN-c3 received a score of 1 due to the limited evidence surrounding its safety and efficacy."

Answered by AI

In which areas can this research take place?

"Currently, the investigation is being conducted in 4 distinct areas. These sites are based in Detroit, San Antonio and Houston as well as other cities with additional centres. It may be useful to select a clinic that is nearest your abode so you can limit time spent travelling for trial purposes if participants decide to partake."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of ZN-c3 in Participants With Solid Tumors

2019. "A Study of ZN-c3 in Participants With Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04158336.